E-DNA IM or ID delivery prime enhances antibody and T cell responses following recombinant gp120 env boost

Na Hutnick,J Pollara,K Broderick,D Montefiori,N Sardasai,M Karuppiah,S Barnett,M Morrow,Dj Myles,G Ferrari,J Yan,Db Weiner

doi:10.1186/1742-4690-9-s2-p364

Abstract

Background The results of the RV144 trial support the ability of vaccine induced Antibodies to protect from HIV acquisition. The STEP trial also appears to have impacted viral load in individuals who produced strong T cell immunity. The HVTN has recently reported that our enhanced DNA (Pennvax) can drive T cell immunity as robust as Adenoviral and Pox platforms in an accelerated format in humans. We have now focused on further driving T and B cell immunity by utilizing prime boost Methods Groups of rabbits or Indian Rhesus macaques were vaccinated with enhanced DNA vaccine plasmids encoding pGAG, pPOL + combinations of 3-5 consensus or COT designed envelopes that were either gp140 or gp160 constructs. Both IM as well as a novel minimally invasive skin delivery EP arrays (MID) were studied. DNA vaccinated animals were boosted two months following the final DNA immunization with SF162 gp120 in MF59. Results

Highlights

The results of the RV144 trial support the ability of vaccine induced Antibodies to protect from HIV acquisition
The HVTN has recently reported that our enhanced DNA (Pennvax) can drive T cell immunity as robust as Adenoviral and Pox platforms in an accelerated format in humans
Groups of rabbits or Indian Rhesus macaques were vaccinated with enhanced DNA vaccine plasmids encoding pGAG, pPOL + combinations of 3-5 consensus or COT designed envelopes that were either gp140 or gp160 constructs

Summary

Background

The results of the RV144 trial support the ability of vaccine induced Antibodies to protect from HIV acquisition. The STEP trial appears to have impacted viral load in individuals who produced strong T cell immunity. The HVTN has recently reported that our enhanced DNA (Pennvax) can drive T cell immunity as robust as Adenoviral and Pox platforms in an accelerated format in humans. We have focused on further driving T and B cell immunity by utilizing prime boost

Methods

Results

Conclusion